EFFICACY AND TOLERABILITY OF JANUS KINASE INHIBITOR TOFACITINIB IN JUVENILE LINEAR SCLERODERMA. CASE SERIES OF 5 PATIENTS.

Q4 Medicine
Georgian medical news Pub Date : 2025-01-01
M Osminina, N Podchernyaeva, V Seraya, S Kurbanova, O Batureva, S Chebusheva, O Shpitonkova, A Polyanskaya, A Skakodub, N Ziskina
{"title":"EFFICACY AND TOLERABILITY OF JANUS KINASE INHIBITOR TOFACITINIB IN JUVENILE LINEAR SCLERODERMA. CASE SERIES OF 5 PATIENTS.","authors":"M Osminina, N Podchernyaeva, V Seraya, S Kurbanova, O Batureva, S Chebusheva, O Shpitonkova, A Polyanskaya, A Skakodub, N Ziskina","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>to analyze the efficacy of the Janus kinase inhibitor tofacitinib (TF) in children with linear form of juvenile localized scleroderma (JLSL).</p><p><strong>Materials and methods: </strong>5 patients with JLSL were treated with TF, we evaluated the efficacy of therapy retrospectively.</p><p><strong>Results: </strong>The mean disease duration prior to TF therapy was high at 71 months. All patients did not respond well to glucocorticosteroid (Glu) and methotrexate (MTX) therapy, two did not respond to combination therapy of Glu, MTX, mycophenolate mofetil (MFM), which prompted the initiation of TF therapy. All patients received TF in combination with MFM or MTX or GCS. The mean duration of TF therapy was 12.8±1.78 months. From 3 to 6 months of TF therapy, we observed positive changes in scleroderma skin and joint involvement. The positive results continued to increase up to the 12th month of treatment, as evidenced by the reduction of the mLoSSI and LoSDI indices. We decided to continue treatment for up to 18 months. The patients tolerated TF well, there were no serious infections, abnormalities in liver function.</p><p><strong>Conclusion: </strong>Our case series showed a significant improvement in skin and joint damage after 12 months of TF therapy in resistant JLSL patients. Further experience with TF is needed to determine its place in the treatment of juvenile scleroderma.</p>","PeriodicalId":12610,"journal":{"name":"Georgian medical news","volume":" 358","pages":"26-30"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Georgian medical news","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: to analyze the efficacy of the Janus kinase inhibitor tofacitinib (TF) in children with linear form of juvenile localized scleroderma (JLSL).

Materials and methods: 5 patients with JLSL were treated with TF, we evaluated the efficacy of therapy retrospectively.

Results: The mean disease duration prior to TF therapy was high at 71 months. All patients did not respond well to glucocorticosteroid (Glu) and methotrexate (MTX) therapy, two did not respond to combination therapy of Glu, MTX, mycophenolate mofetil (MFM), which prompted the initiation of TF therapy. All patients received TF in combination with MFM or MTX or GCS. The mean duration of TF therapy was 12.8±1.78 months. From 3 to 6 months of TF therapy, we observed positive changes in scleroderma skin and joint involvement. The positive results continued to increase up to the 12th month of treatment, as evidenced by the reduction of the mLoSSI and LoSDI indices. We decided to continue treatment for up to 18 months. The patients tolerated TF well, there were no serious infections, abnormalities in liver function.

Conclusion: Our case series showed a significant improvement in skin and joint damage after 12 months of TF therapy in resistant JLSL patients. Further experience with TF is needed to determine its place in the treatment of juvenile scleroderma.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Georgian medical news
Georgian medical news Medicine-Medicine (all)
CiteScore
0.60
自引率
0.00%
发文量
207
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信